Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer

Published:2018-09-01 Issue:9 Volume:4 Page:1179
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Scher Howard I.¹²,Graf Ryon P.³,Schreiber Nicole A.¹,Jayaram Anuradha⁴⁵,Winquist Eric⁶⁷,McLaughlin Brigit¹,Lu David³,Fleisher Martin⁸,Orr Sarah³,Lowes Lori⁶⁷,Anderson Amanda³,Wang Yipeng³,Dittamore Ryan³,Allan Alison L.⁶⁷,Attard Gerhardt⁴⁵,Heller Glenn⁹

Affiliation:

1. Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

2. Department of Medicine, Weill Cornell Medical College, New York, New York

3. Epic Sciences, San Diego, California

4. Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom

5. The Royal Marsden National Health Service Foundation Trust, London, United Kingdom

6. Department of Oncology, Western University, London, Ontario, Canada

7. London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada

8. Clinical Chemistry Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

9. Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference30 articles.

1. Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.;Gillessen;Eur Urol,2018

2. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.;Schrader;Eur Urol,2014

3. Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone.;Rathkopf;Clin Cancer Res,2017

4. Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for =24 weeks in Europe;de Bono;Eur Urol

5. Emerging categories of disease in advanced prostate cancer and their therapeutic implications.;Aggarwal;Oncology (Williston Park),2017

Cited by 183 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatments Targeting the Androgen Receptor and Its Splice Variants in Breast Cancer;International Journal of Molecular Sciences;2024-02-02

2. Hormone-dependent cancers;Steroid Hormone Receptors in Health and Disease;2024

3. Molecular biomarkers in prostate cancer;Biomarkers in Cancer Detection and Monitoring of Therapeutics;2024

4. Exploiting the DNA Damage Response for Prostate Cancer Therapy;Cancers;2023-12-23

5. Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2023-12-06